Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-05-26 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
The Company has entered into a license and supply agreement with SteinCares.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a license and supply agreement between Lupin Limited and SteinCares for commercialization of a biosimilar product in Latin America. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on a business partnership and product commercialization, with no financial statements, earnings data, or regulatory filings related to financial performance. It is not an annual report, earnings release, or management discussion. It is a corporate announcement about a commercial agreement, which fits best under Capital/Financing Update (CAP) as it relates to business development and potential revenue streams. The document length is over 6000 characters and contains substantive information, not just a brief announcement or certification, so it is not RPA or RNS. Therefore, the most appropriate classification is CAP with high confidence.
2025-05-26 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, describing a conversion of loan to equity in a subsidiary company, Lupin Oncology Inc. It provides detailed information about the transaction, the entities involved, shareholding changes, and regulatory compliance. The document is an announcement of a corporate action related to capital structure and subsidiary status, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather a regulatory disclosure about a financing-related transaction. Therefore, it fits best under Capital/Financing Update (CAP). The document length (6837 characters) and content confirm it is a detailed update rather than a brief announcement or a full report.
2025-05-23 English
Disclosure pursuant to Regulation 30 of SEBI Listing Regulations, 2015.
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, describing a conversion of loan to equity in a subsidiary company, Lupin Oncology Inc. It provides detailed information about the transaction, the entities involved, shareholding structure, and regulatory compliance. The document is an announcement of a capital restructuring event involving related parties and subsidiaries. It does not contain financial statements or detailed financial performance data, nor is it a full report or earnings release. It is a regulatory disclosure about a capital/financing update event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6837 characters) and content support this classification with high confidence.
2025-05-23 English
Transcript of the Investors Meet 2025
Call Transcript Classification · 95% confidence The document is a transcript of an Investors Meet held by Lupin Limited on May 15, 2025. It includes detailed presentations by the company's CEO, Managing Director, and CFO, discussing company performance, strategy, market position, and future outlook. The text contains a safe harbor statement typical of investor presentations and includes a Q&A session indication. The document is lengthy (15,000 characters) and contains substantive content rather than just an announcement or a brief summary. It is not an earnings release, annual report, or regulatory filing but a full transcript of an investor meeting. Therefore, the appropriate classification is Call Transcript (CT).
2025-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a transcript of an Investors Meet held by Lupin Limited on May 15, 2025. It includes detailed presentations by the company's CEO, Managing Director, and CFO, discussing company performance, strategic growth drivers, market positions, and future outlook. The text contains a full transcript of the event, including management speeches and Q&A, rather than just an announcement or summary. The document is lengthy (15,000 characters) and contains substantive content typical of a call or meeting transcript. The mention of an investor meet and the detailed presentation and Q&A format aligns with the definition of a Call Transcript (CT). It is not an earnings release (ER) as it is more comprehensive and includes management discussion, nor is it an investor presentation (IP) since it is a transcript, not just slides or presentation materials. Therefore, the appropriate classification is Call Transcript (CT).
2025-05-21 English
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers.
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 20, 2025, from Lupin Limited announcing a partnership with Honeywell to use a new propellant technology in inhalers. It is addressed to stock exchanges and references regulatory disclosure requirements (SEBI Listing Regulations). The content focuses on a business development and product innovation announcement rather than financial results, management changes, or regulatory filings. It does not contain financial statements, voting results, or executive compensation details. The document is approximately 6900 characters, which is relatively short and typical for a press release. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification. The document is best classified as a Capital/Financing Update (CAP) because it announces a significant business development related to product innovation and potential future capital implications, which fits the category of updates on company activities that may affect financing or capital structure indirectly. Therefore, the most appropriate classification is CAP with high confidence.
2025-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.